Mass Spectrometry of Biopharmaceuticals – improved methodologies for qualitative, quantitative and structural characterisation of drugs, proteinaceous drug targets and diagnostic molecules. (Q84230): Difference between revisions
Jump to navigation
Jump to search
(Changed label, description and/or aliases in 1 language: translated_label) |
(Changed label, description and/or aliases in 2 languages: Changing unique label-description pair) |
||
| description / en | description / en | ||
Project in Poland | Project Q84230 in Poland | ||
| description / pl | description / pl | ||
Projekt w Polsce | Projekt Q84230 w Polsce | ||
Revision as of 05:22, 29 October 2020
Project Q84230 in Poland
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Mass Spectrometry of Biopharmaceuticals – improved methodologies for qualitative, quantitative and structural characterisation of drugs, proteinaceous drug targets and diagnostic molecules. |
Project Q84230 in Poland |
Statements
3,499,706.0 zloty
0 references
3,499,706.0 zloty
0 references
100.0 percent
0 references
1 November 2017
0 references
31 October 2020
0 references
INSTYTUT BIOCHEMII I BIOFIZYKI POLSKIEJ AKADEMII NAUK
0 references
Mass Spectrometry (MS) expands into almost every area that requires qualitative and quantitative analysis of small molecules, including clinical applications. Its advantages include unsurpassed specificity, sensitivity better than most other analytical techniques, and ability to multiplex the analysis of many compounds in one analytical run. Since 2001 MS Lab IBB serves as a core MS laboratory for the community of biomedical sciences, implementing a variety of proteomic/metabolomic analyses for research groups from >70 institutions worldwide, both from academia and biopharma industry. It also provides immunosuppressive drug monitoring service for Polish transplant patients. We collaborate with numerous research groups from Poland and abroad, work out new data analysis tools and train students. Present project aims at improvements in analytical capabilities of the Lab and implementation of new procedures that will increase the scope of Lab activities or increase the results quality. (Polish)
0 references
Mass Spectrometry (MS) expands into almost every area that requires qualitative and quantitative analysis of small molecules, including clinical applications. It advantages include unsurpassed specificity, sensitivity better than most other analytical techniques, and ability to multiplex the analysis of many compounds in one analytical run. Since 2001 MS Lab IBB serves as a core MS laboratory for the community of biomedical sciences, implementing a variety of proteomic/metabolomic analyses for research groups from >70 institutions worldwide, both from academia and biopharma industry. It also provides immunosuppressive drug monitoring service for Polish transplant patients. We cooperate with numerous research groups from Poland and abroad, work out new data analysis tools and train students. Present project aims at improvements in analytical capabilities of the Lab and implementation of new procedures that will increase the scope of Lab activities or increase the results quality. (English)
14 October 2020
0 references
Identifiers
POIR.04.04.00-00-2CC8/16
0 references